Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Incyte INCY also declined after study data disappointed investors. Shares of Sarepta Therapeutics plunged earlier in the week after it reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). Per the company, this patient died of acute liver failure. While acute liver injury is a known risk of Elevidys, this is the first time a death has been reported of anyone taking the therapy. However, Sarepta stated that the patient also had a recent cytomegalovirus (CMV) infection, which may have contributed to the outcome, as CMV can damage the liver. Sarepta has reported the event to health authorities, clinical study investigators and prescribing physicians. It intends to update Elevidys'
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTPR Newswire
- Is This Stock a Buy After a Massive 20% Drop in 1 Day? [Yahoo! Finance]Yahoo! Finance
- Hansa Biopharma publishes 2024 Annual and Sustainability Reports [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Scotiabank from $105.00 to $80.00. They now have a "sector perform" rating on the stock.MarketBeat
SRPT
Earnings
- 2/26/25 - Beat
SRPT
Sec Filings
- 3/13/25 - Form 4
- 3/12/25 - Form 144
- 3/11/25 - Form 4
- SRPT's page on the SEC website